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This study examined the effects of intracerebroventricularly
(i.e.v.) administered somatostatin (SRIH-14 or SRIH-28) on growth and
function of pituitary somatotropes (GH cells). Female rats were
subjected to intracerebroventricular administration of three 1g doses
of SRIH-14 or SRIH-28 every second day. Blood samples were
collected for hormone analyses and pituitaries were removed for
histological and morphometric evaluation, five days after the last
injection. Compared to control animals, SRIH treatment decreased
(p<O.05) all morphometric measurements obtained for GH cells. The
concentration of serum growth hormone (GH) in SRIH-14- or
SRIH-28-treated groups was lower (p<O.05) by 69% and by 61%
respectively, in comparison to control rats. Thesefindings suggest that
centrally administered somatostatin is specifically involved in the
control of growth and secretory activity of GH cells. Thus,
pharmacological manipulation of SRIH receptors reached from
cerebrospinal fluid may alter the systemic effects of GH.
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INTRODUCTION
Somatostatin (somatotropin release-inhibiting hormone; SRIH), is a neuro-
peptide initially described as inhibiting growth hormone release from the pituitary
gland (Brazeau et al. 1973). There are two major forms of somatostatin, a cyclic
tetradecapeptide somatostatin-14 (SRIH-14), originally isolated from bovine hy-
pothalamic extracts, and an N-terminally elongated form consisting of 28 amino
acid residues, octacosapeptide somatostatin-28 (SRIH-28) (Reichlin 1983). Both
somatostatins are widely distributed in the central and peripheral nervous system
(Raulf et al. 1994). In the central nervous system SRIH acts as a neurotransmitter
and/or neuromodulator and affects locomotor activity, cognitive functions and
behavioral processes (Epelbaum 1986). Both peptides are also present in non-
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neuronal tissues such as the gastrointestinal tract and endocrine tissues including
the pancreas, thyroid and adrenal gland (Reichlin 1983). Somatostatin inhibits the
secretion of several non-pituitary hormones such as insulin, glucagon, gastrin,
secretin and aldosterone (Epelbaum et al. 1995).
It is well known that SRIH inhibits the release of growth hormone (GH) from
somatotropes in male rats (Milosevic et al. 1998) via separate receptors in the
plasma membrane (Wehrenberg et al. 1982). Hyphothalamic SRIH also inhibits
the secretion of luteinising hormone (lovren et al. 1998), prolactin (PRl) (Milosevic
et el. 1998), thyrotropin-stimulating hormone (TSH) (Epelbaum 1994) from the
anterior pituitary.
This study was designed to evaluate the effects of intracerebroventricular
(i.c.v.) administration of low doses of SRIH-14 and SRIH-28 on the morphology
and secretory activity of somatotropes in pituitary glands of female rats.
MATERIAL AND METHODS
The study was performed on adult female Wistar rats (210-230 g), bred in
the Institute for Biological Research in Belgrade. Rats were kept under a 12:12 h
light-dark cycle, at 22 ± 2 C. They were fed with special food for laboratory rats
(prepared by D.D.Veterinarski Zavod Subotica, Subotica, Yugoslavia). Food and
water were available to the rats ad libitum.
Animal preparation. Surgical procedures were performed under ether anes-
thesia (aether ad narcosis Ph. lug. III. produced by "lek", ljubljana, Slovenia).
The rats were implanted with a headset later used for i.c.v. injections. A minimum
recovery time of 5 days was permitted before the onset of experiments. The
headset consisted of a silastic-sealed 20-gauge cannula (Starcevic et al. 1998),
implanted into the lateral cerebral ventricle, 1 mm posterior and 1.5 mm lateral to
the bregma, and 3 mm below the cortical surface. A small stainless steel anchor
screw was placed at a remote site on the skull. The cannula and screw were
cemented to the skull with dental acrylic (Simgal; ICN Galenika, Belgrade, Yugo-
slavia).
Treatment of animals. After the rats recovered from surgery they were divided
into three experimental groups of five animals per group. The first and second
groups consisted of rats which were given (i.c.v.) three 1-f.lgdoses of SRIH-14 (S
9129; Sigma, St. louis, Mo., USA) or SRIH-28 (S 6135; Sigma, St. louis, Mo.,
USA) dissolved in 5 ul, saline. The third group was a control group, comprised of
rats treated in the same manner, except that they received only 5 ul, of saline i.c.v,
All animals were sacrificed by decapitation during deep anesthesia 5 days after
the last injection.
Light microscopy and immunocytochemistry. Pituitary glands were excised,
fixed in Bouins solution for 48 h and embedded in paraffin. Serial surn thick tissue
sections were deparaffinized in xylol and serial alcohol dilutions. Pituitary hor-
mones were localized by the peroxidase-antiperoxidase-complex (PAP) method
of Sternberger et. al. (1970). Endogenous peroxidase activity was blocked by
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incubation in 9 mmol/L hydrogen peroxide in methanol for 30 min at ambient
temperature. Before application of specific primary antisera, nonspecific back-
ground staining was minimized by incubation of the sections with non-immune,
porcine serum diluted with phosphate buffered saline pH 7.4 (PBS) for 60 min.
Sections were then overlaid with the appropriate dilutions of the specific primary
antibodies (hGH-antisera, Dako A/S, Glostrup, Denmark) for 24 h at 4 °C. After
washing in PBS, sections were incubated for another 60 min with the second
antibody-swine-antirabbit IgG for 45 min, rinsed again with PBS for 10 min and
incubated with rabbit PAP serum for 45 min. Antibody localization was visualized
by incubating the sections in Tris-HCI buffered saline (0.05 mol/L, pH 7.4)
supplemented with 3,3-diaminobenzidine tetrachloride (DAB) (Serva, Heidelberg,
Germany) and 9 mmol/L hydrogen peroxide. Slides were throughly washed under
running tap water, counterstained with hematoxylin and mounted in Canada
balsam (Alkaloid, Skopje, Macedonia). Control sections were incubated without
primary antisera or by substituting non-immune rabbit serum for the primary
antiserum.
Morphometry. Measurements were performed on the widest portion of the
pituitary gland and immunocytochemically-labelled GH cells were analyzed by
the M42 test system of Weibel (1979). The formula of Weibel and Gomez (1962)
was used for calculation of the cell and nuclear volumes
Hormone assay. Serum concentrations of GH in control and experimental
rats were measured by the Delfia method (hGH-Delfia kits, LKB, Turky, Finland).
Statistical analyses. Biochemical and morphometric data obtained from
each group were averaged, and the standard deviation of the mean was calcu-
lated. A one-way analysis of variance (ANOVA), followed by the multiple range
test of Duncan (Pharmacological Calculation System, 1986) was used for statisti-
cal comparisons between groups. A probability value of 5% or less was consid-
ered statistically significant.
RESULTS
Data for the body weight, absolute and relative weight of the pituitary in
SRIH-treated groups and controls are summarized in Table 1.
Table 1. The effects of intracerebrovenricularly administered SRIH-14 or SRIH-28 on body weight
and absolute and relative weight of the pituitary in adult female rats. (means ± SD; n=5)
Experimental group Body weight Absolute pitutary Relative pitutary weight(g) weight (mg) (mg/100g)
------_.__-..,-------
Control 238 ± 6.4 10.5 ± 0.4 4.3 ± 0.1
SRIF-14 234 ± 4.0 9.2 ± 0.6 3.9 ± 0.2
SRIF-28 220 ± 12.2* 10.0 ± 0.4 4.1 ± 0.4
-~-~~------
The values are the means ± S.D. for five animals. * p<0.05.
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As can be seen, a significant (p<0.05) decrease of body weight by 10% was
observed only in rats treated with SRIH-28 in comparison with controls. Absolute
and relative pituitary weights were not significantly (p<0.05) decreased in either
group of SRIH-treated animals compared with corresponding controls. Somatot-
ropes were the predominant cell type in the anterior pituitary lobe of the adult
female rat (Table 2).
Table 2. Mcrphometric parameters of the GH cells of the pituitary after intracerebroventricular
administration of SRIH-14 or SRIH-28 in female rats. (means z SO; n=5)
Experimental group Volume of the GH cells Volume of the GH Volume density of the(jlm 3) nucelei (jlm3) GH cells (%)
Control 1433±31.9 137±13.4 42±1.5
SRIF-14 1044±44.5* 104±4.2* 32±O.1*
(-27%) (-24%) (-24%)
SRIF-28 751±42.4* 75±4.2* 28±1.4*
(-48%) (-45%) (-33%)
* p<O.05, in comparison with controls
Immunocytochemically identified GH cells in control rat pituitaries ranged
from ovoid to pyramidal in shape, with a spherical centrally located nucleus. GH
cells were usually situated along sinusoids (Fig. 1A). In SRIH-treated pituitaries,
GH cells were smaller, irregularly shaped, with more intensely stained secretory
granules (Figs. 1B, 1C). Blood capillaries were dilated (Fig. 1B). All morphometric
parameters were significantly (p<0.05) decreased in both SRIH-treated groups
compared with controls (Table 2). The serum concentration of GH was signifi-
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Fgure 1. Immunohistochemically labeled GH cells in : A control rats. B SRIH-14 and C SRIH-28
intracerebroventrculary rats (PAP, 1256 x). -7indicate cells, * indicates blood camplaries.
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Fgure 2. Serum concentrations of GH after intracerebroventricular administration of SRIH-14 or
SRIH-28 in adult female rats. Data are expressed as mean values ± S.D.(n=5), *p<O.05 in
comparison with controls.
cantly decreased (p<0.05) by 69% and by 61 % respectively after i.c.v. SRIH-14
or SRIH-28 treatment, in comparison to controls (Fig. 2)
DISCUSSION
The presented results clearly demonstrate that repeated i.c.v. administration
of SRIH-14or SRIH-28significantly decreased all measured morphometric indices
of somatotropes. The secretion of anterior pituitary hormones is regulated mainly
by hypothalamic releasing and inhibiting hormones (Meyerhof et al. 1992). It is
well know that SRIH inhibits release of GH from somatotropes via separate
receptors in the plasma membrane (Wehrenberg et al. 1982; Epelbaum et al.
1987). Control of hormone secretion involves many cell surface receptors and
activation of multiple cellular pathways such as mobilization of calcium, cyclic
AMP, diacylglycerol (Chen and Clarke 1992). Local application of somatostatin
peptides induces hyperpolarization of somatotropes and inhibition of adenylate
cyclase (Chen et al. 1994) with modulation of calcium currents (Meyerhof et al.
1992).
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A number of physiological and biochemical studies in vivo and in vitro have
been performed to examine the role of both somatostatins on the mechanism of
GH secretion (Epelbaum 1986; Epelbaum et al. 1987; Blanchard et al. 1988;
Tannenbaum 1988). By contrast, only a few studies have investigated
morphological features of somatotropes during inhibition or stimulation of GH
secretion (Shimada and Tosaka-Shimada 1989; Shimada et al. 1990). Shimada
et al. (1990) suggest that inhibition of GH release by SRIH involves a change in
the distribution of microfilaments rather than microtubules. These authors found
microfilament bundles running parallel to the plasmalemma in the space between
granules at 2 and 5 minutes after injection of SRIH.
We have previously observed that both types of SRIH given i.c.v. to male
rats led to a decrease in the number of GH cells, accompanied by a reduction in
both their cellular and nuclear volumes in comparison with controls (Milosevlc et
al. 1998).
In summary, an intermittent exposure of female rats to i.c.v. SRIH-14 or
SRIH-28 reduces serum GH concentrations with corresponding changes in
morphology of pituicytes that secrete these hormones. Pharmacological
manipulation of these central SRIH receptors may then alter GH physiology.
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MORFOM~TRIJSKE I FUNKCIONALNE PROMENE SOMATOTROPNIH CELIJA HIPOFIZE
ZENKI PACOVA POSLE CENTRALNE APLIKACIJE SOIl/lATOSTATINA
VERICA MILOSEVIC, MIRJANA LOVREN, MILKA SEK\,JLlC,. BRANISLAVA BRKIC, S. VELKOVSKI
VESNA STARCEVIC
SADRZAJ
Ispitivani su efekti intraeerebroventrikularno (i.e.v.) ubrizganih somatostat-
ina (SRIH-14 iii SRIH-28) na rast i funkeiju somatotropnih 6elija hipofize zenki
paeova. Sve eksperimentalne zlvotinje su primale po 1fl9 SRIH-14 iii SRIH-28
rastvorenog u 5flL fizioloskoq rastvora, svaki drugi dan. Kontrole su na isti nacin
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injecirane fiziolosklrn rastvorom. Zivotinje su zrtvovane petog dana po poslednjoj
primljenoj dozi. Krv je sakupljana za odredjivanje koncentracije hormona rasta
(GH) u serumu, a hipofize su pripremane za histolosku i morfometrijsku analizu.
Dobijeni rezultati pokazuju da SRIH tretirane zivotinje pokazuju znacajno sman-
jenje (p< 0.05) svih ispitivanih morfometrijskih parametara (volumen 6elija i jedara,
volumenska gustina) u odnosu na kontrolu. Koncentracija GH u serumu SRIH·14
i SRIF-28 tretiranih zenki takodje je znacajno smanjena (p<0.05) za 69% odnosno
61% u poredjenju sa kontrolnim zenkarna, Na osnovu ovako dobijenih rezultata
rnoze se zakljuciti da oba aplikovana somatostatina inhibiraju rast i sekretornu
aktivnost somatotropnih 6elija hipofize.
